Pharma Mar (NASDAQ:PHMMF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday. The brokerage currently has a $4.75 price objective on the stock. Zacks Investment Research‘s target price would indicate a potential upside of 17.28% from the stock’s previous close.

According to Zacks, “Pharma Mar SA is a biopharmaceutical company. It engaged in the discovery and development of marine-derived anticancer drugs. The company’s product pipeline consists of PM1183, plitidepsin, and PM184 which are in clinical trial stage. It operates primarily in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. Pharma Mar SA is headquartered in Madrid, Spain. “

Pharma Mar (NASDAQ:PHMMF) opened at 4.05 on Tuesday. The firm’s market cap is $1.00 billion. The company has a 50-day moving average of $4.42 and a 200-day moving average of $4.09. Pharma Mar has a 52 week low of $2.40 and a 52 week high of $4.80.

TRADEMARK VIOLATION WARNING: This report was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/09/21/pharma-mar-phmmf-rating-increased-to-buy-at-zacks-investment-research.html.

Receive News & Stock Ratings for Pharma Mar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Mar and related stocks with our FREE daily email newsletter.